A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)

Study Identifier
PCYC-0216
CT.gov Identifier
NCT00076401
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Other
Sign up for trial alerts

Study Details

Medical Condition
  • Blood Cancer - Leukemia (Other)
  • Blood Cancer - Chronic Lymphocytic Leukemia (CLL)
    • Study Drug
  • Motexafin gadolinium
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * At least 18 years old * Refractory or relapsed CLL * ECOG performance status score of 0, 1, or 2 * Each patient must sign a study-specific informed consent form
    Exclusion Criteria:
    Laboratory values of: * Platelet count \<30,000/uL * AST or ALT \>2 x the upper limit of normal (ULN) * Total bilirubin \>2 x ULN * Creatinine \>2.0 mg/dL * Chemotherapy, radiation therapy, immunotherapy, systemic corticosteroids, or systemic biologic anticancer therapy within 21 days before beginning study treatment * Women who are pregnant or lactating

    Protocol Summary

    The purpose of this study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have chronic lymphocytic leukemia (CLL) that has come back after treatment or that has stopped responding to treatment.

    Study Locations

    Location
    Status
    Location
    Ohio State University Medical Center
    Columbus, Ohio, United States
    Status
    Not applicable